NCT04621435: Imaging of Solid Tumors Using 68Ga-FAP-2286

NCT04621435
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are eligible for cohorts 1 & 2
Exclusions: 
https://ClinicalTrials.gov/show/NCT04621435

Comments are closed.

Up ↑